Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system - too little activation is bad, too much is even worse

@article{Parsons2007MemantineAN,
  title={Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system - too little activation is bad, too much is even worse},
  author={Chris G. Parsons and Albrecht St{\"o}ffler and Wojciech Danysz},
  journal={Neuropharmacology},
  year={2007},
  volume={53},
  pages={699-723}
}
The neurotransmitter glutamate activates several classes of metabotropic receptor and three major types of ionotropic receptor--alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), kainate and N-methyl-D-aspartate (NMDA). The involvement of glutamate mediated neurotoxicity in the pathogenesis of Alzheimer's disease (AD) is finding increasing scientific acceptance. Central to this hypothesis is the assumption that glutamate receptors, in particular of the NMDA type, are overactivated… Expand
Therapeutic significance of NR2B-containing NMDA receptors and mGluR5 metabotropic glutamate receptors in mediating the synaptotoxic effects of β-amyloid oligomers on long-term potentiation (LTP) in murine hippocampal slices
TLDR
It is demonstrated that glutamate receptor antagonists delivered at concentrations which still allow physiological activities in vitro, are able to prevent Aβ(1-42) oligomer-induced synaptic toxicity and further support the glutamatergic system as a target for the development of improved symptomatic/neuroprotective treatments for AD. Expand
The fraction of activated N-methyl-d-Aspartate receptors during synaptic transmission remains constant in the presence of the glutamate release inhibitor riluzole
TLDR
The fraction of NMDA receptors contributing to postsynaptic events in the presence of therapeutically relevant concentrations of the GRI riluzole was determined using an in vitro hippocampal slice preparation and it is likely that NMDA receptor antagonists would be able to exert additional therapeutic effects in combination therapy with GRIs. Expand
NMDA-gated ion channel research and its therapeutic potentials in neurodegenerative diseases: a review
TLDR
Open-channel blockers with uncompetitive antagonism and drugs modulating NMDAR activities are appealing therapeutic strategies because, in theory, these properties could decrease neurotoxicity due to excessive levels of glutamate while sparing physiological neurotransmission. Expand
Mechanisms of NMDA receptor inhibition by memantine and ketamine
NMDA receptors (NMDARs), a subfamily of ionotropic glutamate receptors, have unique biophysical properties including high permeability to Ca2+. Activation of NMDARs increases the concentration ofExpand
In vivo evidence for functional NMDA receptor blockade by memantine in rat hippocampal neurons
TLDR
Therapeutic doses of memantine are able to antagonize NMDA receptor-mediated activity in the principal cells of the hippocampus in vivo, i.e. in the presence of physiological concentrations of Mg2+. Expand
Adenosine A2A Receptor Antagonists Affects NMDA Glutamate Receptor Function. Potential to Address Neurodegeneration in Alzheimer’s Disease
TLDR
A2AR antagonists such as istradefylline, which is already approved for Parkinson’s disease, have potential to afford neuroprotection in AD in a synergistic-like fashion, i.e., via both neurons and microglia. Expand
Role of nonsynaptic GluN2B-containing NMDA receptors in excitotoxicity: Evidence that fluoxetine selectively inhibits these receptors and may have neuroprotective effects
TLDR
Under hypoxic conditions, it is likely that the failure of synaptic glutamatergic transmission, the impairment of the GluN2A-activated neuroprotective cascade, and the persistent over-activation of extrasynaptic Glu2B-containing NMDARs lead to excitotoxicity. Expand
Activation of Brain Histaminergic Neurotransmission: A Mechanism for Cognitive Effects of Memantine in Alzheimer's Disease
TLDR
The increase in brain t-MeHA levels after single or repeated administration of therapeutic doses of memantine suggests that the drug exerts its beneficial effects on cognitive deficits of Alzheimer's disease, at least partly, by activating histamine neurons. Expand
Synapses, NMDA receptor activity and neuronal Aβ production in Alzheimer’s disease
TLDR
Recent data suggest that chronic activation of extrasynaptic NMDA receptors leads to a sustained neuronal amyloid-β release and could be involved in the pathogenesis of Alzheimer’s disease, which could explain why memantine is, to date, the only clinically approved NMDA receptor antagonist for the treatment of dementia. Expand
Glutamatergic dysfunctioning in Alzheimer's disease and related therapeutic targets.
TLDR
It is proposed that NMDAR antagonists with tolerable side-effects, ion channel blockers with low affinity, glycine site agents, and specific antagonists of polyamine site and GluN2B subunit may have therapeutic potential for present and future drug development. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 280 REFERENCES
The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence
TLDR
It is suggested that glutamate receptors of the N‐methyl‐D‐aspartate (NMDA) type are overactivated in a tonic rather than a phasic manner in Alzheimer's disease, and memantine would be expected to improve both symptoms (cognition) and to slow down disease progression because it takes over the physiological function of magnesium. Expand
Neuroprotective and symptomatological action of memantine relevant for alzheimer’s disease — a unified glutamatergic hypothesis on the mechanism of action
TLDR
It is postulate that if in Alzheimer’s disease overactivation of NMDA receptors occurs indeed, memantine would be expected to improve both symptoms (cognition) and slow down disease progression because it takes over the physiological function of magnesium. Expand
Frequency-dependent involvement of NMDA receptors in the hippocampus: a novel synaptic mechanism
TLDR
It is described how NMDA receptors can participate during high-frequency synaptic transmission in the hippocampus, their involvement during low-frequency transmission being greatly suppressed by Mg2+. Expand
Modulation of learning processes by ionotropic glutamate receptor ligands.
TLDR
The present paper reviews the literature dealing with the role of NMDA receptor antagonists in learning and possible consequences for the therapy of dementia, and suggests that positive modulation of these receptors could result in cognitive enhancement that might find therapeutic application. Expand
Memantine Blocks α7* Nicotinic Acetylcholine Receptors More Potently Than N-Methyl-D-aspartate Receptors in Rat Hippocampal Neurons
The N-methyl-d-aspartate (NMDA) receptor antagonist memantine is an approved drug for treatment of Alzheimer's disease (AD). Other such treatments are cholinesterase inhibitors and nicotinicExpand
Memantine blocks alpha7* nicotinic acetylcholine receptors more potently than n-methyl-D-aspartate receptors in rat hippocampal neurons.
TLDR
It is suggested that blockade of alpha7(*) nAChRs by memantine could decrease its effectiveness for treatment of AD, particularly at early stages when the degrees of nA cholinergic dysfunction and of cognitive decline correlate well. Expand
Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity
TLDR
Low micromolar concentrations of memantine, levels known to be tolerated by patients receiving the drug for the treatment of Parkinson's disease, prevent NMDA receptor-mediated neurotoxicity in cultures of rat cortical and retinal ganglion cell neurons; memantine also appears to be both safe and effective in a rat stroke model, suggesting that memantine has considerable therapeutic potential for the myriad of clinical entities associated with NMda receptor- mediated neurotoxicity. Expand
Glutamate becomes neurotoxic via the N-methyl-d-aspartate receptor when intracellular energy levels are reduced
TLDR
The results show that the transition of glutamate from neurotransmitter to neurotoxin is facilitated when cellular energy is limited in cultured cerebellar neurons, demonstrating that glucose metabolism, ATP production, and functioning Na+,K+-ATPases are necessary to generate a resting potential sufficient to maintain the voltage-dependent Mg2+ block of the NMDA receptor channel. Expand
Memantine is a clinically well tolerated N-methyl-d-aspartate (NMDA) receptor antagonist—a review of preclinical data
TLDR
Preclinical data on memantine is summarized to provide evidence that it is indeed possible to develop clinically well tolerated NMDA receptor antagonists, a fact reflected in the recent interest of several pharmaceutical companies in developing compounds with similar properties to memantine. Expand
Potential role of N-methyl-D-aspartate receptors as executors of neurodegeneration resulting from diverse insults: focus on memantine.
TLDR
The mechanisms leading to the condition of chronically depolarized membranes on vulnerable neurons in the Alzheimer's disease brain are likely due to a complex interaction between oxidative stress, mitochondrial failure, chronic brain inflammation and the presence of amyloid-beta and hyperphosphorylated-tau. Expand
...
1
2
3
4
5
...